StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $4.45 | $4.54 | +2.02% | 0.1M |
| 05-12 | $4.60 | $4.56 | -0.87% | 0.1M |
| 05-13 | $3.60 | $2.67 | -25.83% | 6.8M |
| 05-14 | $2.71 | $2.52 | -7.01% | 1.6M |
| 05-15 | $2.48 | $2.68 | +8.06% | 2.2M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $8.90M | $45.15M | $31.95M | $20.38M |
Operating Income | $-8.41M | $-26.95M | $-23.68M | $-14.66M |
Net Income | $1.54M | $-39.23M | $-29.47M | $-8.29M |
EPS (Diluted) | $0.03 | $-1.84 | $-1.72 | $-0.65 |
Total Assets | $70.98M | $35.33M | $36.46M | $41.32M |
Total Liabilities | $58.17M | $69.19M | $63.19M | $60.74M |
Cash & Equivalents | $56.55M | $20.44M | $22.69M | $26.49M |
Free Cash Flow OCF − CapEx | $-6.62M | $-18.93M | $-16.41M | $-12.48M |
Shares Outstanding | 61.41M | 50.00M | 49.89M | 37.98M |
No sell-side coverage available for TLSI.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Fundamentals not available for TLSI.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.